Related references
Note: Only part of the references are listed.Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes
Asa K. Davis et al.
DIABETES CARE (2015)
Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial
John M. Lachin et al.
DIABETES (2014)
Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study
A. Barker et al.
DIABETES OBESITY & METABOLISM (2014)
Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study
P. McGee et al.
DIABETIC MEDICINE (2014)
Why were we wrong for so long? The pancreas of type 1 diabetic patients commonly functions for decades
Denise L. Faustman
DIABETOLOGIA (2014)
The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells
Richard A. Oram et al.
DIABETOLOGIA (2014)
Prediction Is Very Hard, Especially About the Future: New Biomarkers for Type 2 Diabetes?
William L. Lowe et al.
DIABETES (2013)
Residual β-Cell Function 3-6 Years After Onset of Type 1 Diabetes Reduces Risk of Severe Hypoglycemia in Children and Adolescents
Jesper S. Sorensen et al.
DIABETES CARE (2013)
Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents
Johnny Ludvigsson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay
Limei Wang et al.
DIABETES CARE (2012)
Alternative Markers of Hyperglycemia and Risk of Diabetes
Stephen P. Juraschek et al.
DIABETES CARE (2012)
Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes
W. J. Kim et al.
DIABETIC MEDICINE (2012)
Continuous Glucose Monitoring after Islet Transplantation in Type 1 Diabetes: An Excellent Graft Function (β-Score Greater Than 7) Is Required to Abrogate Hyperglycemia, Whereas a Minimal Function Is Necessary to Suppress Severe Hypoglycemia (β-Score Greater Than 3)
Marie-Christine Vantyghem et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes
Denise L. Faustman et al.
PLOS ONE (2012)
Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: An 11-year population-based Cohort study in Japan, the Suita study
M. Watanabe et al.
ATHEROSCLEROSIS (2011)
Complications of Type 1 Diabetes
L. Yvonne Melendez-Ramirez et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2010)
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients
Christoph Stettler et al.
DIABETES CARE (2008)
1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes
Kathleen M. Dungan et al.
DIABETES CARE (2006)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
β-cell function and the development of diabetes-related complications in the diabetes control and complications trial
MW Steffes et al.
DIABETES CARE (2003)
Share Paper
